Content about Acura Pharmaceuticals

January 3, 2014

Fruth Pharmacy is seeing a positive response from customers in its efforts to limit the sale of OTC cold and allergy medications that contain pseudoephedrine, according to published reports.

NEW YORK — Fruth Pharmacy is seeing a positive response from customers in its efforts to limit the sale of OTC cold and allergy medications that contain pseudoephedrine, according to published reports.

The West Virginia MetroNews Network reported that Fruth had sold nearly 1,000 boxes of Acura Pharmaceuticals' Nexafed, a nasal decongestant that contains tamper-resistant properties to limit its appeal to makers of methamphetamine, and the product has been popular with customers since its introduction at the stores in August.

November 5, 2013

Acura Pharmaceuticals on Monday announced that Nexafed, its next generation pseudoephedrine with abuse-deterrent technology, will now be stocked by Rite Aid.

PALATINE, Ill. — Acura Pharmaceuticals on Monday announced that Nexafed, its next generation pseudoephedrine with abuse-deterrent technology, will now be stocked by Rite Aid.

Nexafed is a 30 mg immediate-release pseudoephedrine product that combines nasal-congestion relief with a unique technology that disrupts the conversion of pseudoephedrine into methamphetamine.

September 5, 2013

Acura Pharmaceuticals announced a study, published in the September issue of the American Journal of Drug and Alcohol Abuse, that validates the ability of Nexafed to uniquely disrupt the extraction and conversion of pseudoephedrine into methamphetamine.

PALATINE, Ill. — Acura Pharmaceuticals on Tuesday announced a study, published in the September issue of the American Journal of Drug and Alcohol Abuse, that validates the ability of Nexafed to uniquely disrupt the extraction and conversion of pseudoephedrine into methamphetamine. The study also confirms that Nexafed delivers the same efficacy compared to other similar PSE products, Acura claimed. 

August 28, 2013

Fruth Pharmacy is taking up a pseudoephedrine product for nasal congestion designed to deter the manufacturing of methamphetamine at all of its stores, according to published reports.

NEW YORK — Fruth Pharmacy is taking up a pseudoephedrine product for nasal congestion designed to deter the manufacturing of methamphetamine at all of its stores, according to published reports.

The West Virginia MetroNews Network reported that Fruth — which operates 25 stores in West Virginia and Ohio — would start selling Acura Pharmaceuticals' Nexafed at its stores.

July 15, 2013

Acura Pharmaceuticals on Monday announced a second-generation prototype formulation of its methamphetamine-resistant IMPEDE technology with pseudoephedrine hydrochloride yielded no measurable amount of methamphetamine hydrochloride when processed in the direct conversion or one-pot method.

PALATINE, Ill. — Acura Pharmaceuticals on Monday announced a second-generation prototype formulation of its methamphetamine-resistant IMPEDE technology with pseudoephedrine hydrochloride yielded no measurable amount of methamphetamine hydrochloride when processed in the direct conversion or one-pot method.  

March 6, 2013

Acura Pharmaceuticals announced that its next-generation pseudoephedrine with abuse-deterrent technology will now be stocked by North Carolina's Kerr Drug.

PALATINE, Ill. — Acura Pharmaceuticals on Tuesday announced that its next-generation pseudoephedrine with abuse-deterrent technology will now be stocked by North Carolina's Kerr Drug. 

Nexafed is a 30 mg immediate-release pseudoephedrine product that combines effective nasal-congestion relief with a unique technology that disrupts the conversion of pseudoephedrine into methamphetamine, Acura noted. 

December 27, 2012

In support of its December launch of the pseudoehedrine product Nexafed, Acura Pharmaceuticals recently kicked off a national e-mail campaign to help drive pharmacists to the Nexafed website with content specifically designed for the pharmacist audience, including infographics, graphic representations of study data and a behind-the-scenes look at Nexafed's abuse-deterrent technology.

PALATINE, Ill. — In support of its December launch of the pseudoehedrine product Nexafed, Acura Pharmaceuticals recently kicked off a national e-mail campaign to help drive pharmacists to the Nexafed website with content specifically designed for the pharmacist audience, including infographics, graphic representations of study data and a behind-the-scenes look at Nexafed's abuse-deterrent technology.

November 15, 2012

Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine.

SUPPLIER NEWS — Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine. Couched as the “next generation pseudoephedrine product,” Nexafed is a 30 mg PSE hydrochloride tablet that utilizes Acura’s trademarked Impede technology. 


November 8, 2012

Acura Pharmaceuticals on Wednesday shared with analysts details on its launch strategy of Nexafed, a pseudoephedrine formulated such that in inhibits the diversion to methamphetamnine.

PALATINE, Ill. — Acura Pharmaceuticals on Wednesday shared with analysts details on its launch strategy of Nexafed, a pseudoephedrine formulated such that it inhibits the diversion to methamphetamnine. 

October 29, 2012

Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine.

PALATINE, Ill. — Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine. Couched as the "next generation pseudoephedrine product," Nexafed is a 30-mg PSE hydrochloride tablet that utilizes Acura's trademarked Impede technology. 

January 24, 2012

A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.

PALATINE, Ill. — A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.

Acura said it was informed by Pfizer that Oxecta has hit the market in 5-mg and 7.5-mg strengths, which will be sold in 100-count bottles. Oxecta is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

June 22, 2011

The Food and Drug Administration has approved a medication designed to treat acute and chronic moderate to severe pain, where the use of an opioid analgesic is suitable.

NEW YORK — The Food and Drug Administration has approved a medication designed to treat acute and chronic moderate to severe pain, where the use of an opioid analgesic is suitable.

Pfizer and Acura Pharmaceuticals said that their drug Oxecta (oxycodone HCl, USP tablets) is the first tamper-resistant medication designed to deter abuse and misuse with Aversion technology, which is being licensed by Pfizer from Acura.

February 14, 2011

The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

PALATINE, Ill. — The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

Acura Pharmaceuticals announced Monday the acceptance of King Pharmaceuticals’ application for Acurox (oxycodone hydrochloride). King developed the drug using Acura’s Aversion technology, which is designed to limit or impede the ability to abuse the drug by dissolving or crushing the pills and then injecting them.

December 20, 2010

Drug makers King Pharmaceuticals and Acura Pharmaceuticals have submitted a regulatory approval application to the Food and Drug Administration for an opioid pain reliever.

BRISTOL, Tenn. — Drug makers King Pharmaceuticals and Acura Pharmaceuticals have submitted a regulatory approval application to the Food and Drug Administration for an opioid pain reliever.

The two drug makers announced Tuesday the submission for Acurox (oxycodone hydrochloride), an immediate-release tablet for relief of moderate to severe pain.

The tablets use Acura’s aversion technology, designed to deter abuse of the drug by dissolving or crushing the pills.